טוען...
Phase II Study of Cixutumumab in Combination with Temsirolimus in Pediatric Patients and Young Adults with Recurrent or Refractory Sarcoma: A Report from the Children’s Oncology Group
BACKGROUND: The combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mammalian target of rapamycin (mTOR) has shown activity in preclinical models of pediatric sarcoma and in adult sarcoma patients. We evaluated the activity of the anti-IGF-1R antibody cixutumumab with the m...
שמור ב:
| הוצא לאור ב: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4501773/ https://ncbi.nlm.nih.gov/pubmed/25446280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25334 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|